Get started
Author

Christopher H. Yoo

Observed names: C. Yoo, Christopher H Yoo, Christopher Yoo
Observed institutions: Lucile Packard Children's Hospital, Duke University, Stanford Medicine, Stanford Cancer Institute, Saint Louis University, Stanford University
ORCID: 0000-0003-2132-8956
Observed ORCID: 0000-0003-2132-8956
OpenAlex ID: A5050427212
Integrating genomic features for non-invasive early lung cancer detection
2020 · Jacob J. Chabon, Emily G. Hamilton, et al. · Nature · 686
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
2020 · Everett J. Moding, Yufei Liu, et al. · Nature Cancer · 365
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
2020 · Barzin Y. Nabet, Mohammad S. Esfahani, et al. · Cell · 347
PDF
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2020 · Michael S. Binkley, Young-Jun Jeon, et al. · Cancer Discovery · 163
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2020 · Matthew D. Hellmann, Barzin Y. Nabet, et al. · Clinical Cancer Research · 125
Outcomes for pediatric patients with osteosarcoma treated with palliative radiotherapy
2019 · Emily L. Chen, Christopher H. Yoo, et al. · Pediatric Blood & Cancer · 31
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis
2024 · Tej D. Azad, Shigeki Nanjo, et al. · npj Precision Oncology · 13
PDF
Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy
2022 · Claire Baniel, Christopher H. Yoo, et al. · Practical Radiation Oncology · 13
Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience
2019 · Margaret M. Kozak, Christopher H. Yoo, et al. · Journal of Adolescent and Young Adult Oncology · 10
Stage I–II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy
2021 · Michael S. Binkley, Susan M. Hiniker, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2
Orthotopic Liver Transplantation After Stereotactic Body Radiotherapy for Pediatric Hepatocellular Carcinoma with Central Biliary Obstruction and Nodal Involvement
2018 · Emily Chen, Arun Rangaswami, et al. · Cureus · 2
PDF
Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al. · 1
Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer
2022 · Max Devine, David J. Merriott, et al. · Practical Radiation Oncology · 1
KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
2020 · Michael S Binkley, Young-Jun Jeon, et al. · Journal of Clinical Oncology · 1
Low-dose total skin electron beam therapy for refractory cutaneous CD30 positive lymphoproliferative disorders
2019 · Neil Panjwani, Christopher H Yoo, et al. · Journal of Dermatological Treatment · 1
Data from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Supplementary Tables S1-S7 from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Supplementary Figures 1-9 from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Supplementary Tables S1-S7 from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Supplementary Figures 1-9 from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
PDF
Data from KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
2023 · Michael S. Binkley, Young-Jun Jeon, et al.
Table S1 from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
Supplementary Tables S2-S7 from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
Supplementary Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
Supplementary Data from Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
2023 · Matthew D. Hellmann, Barzin Y. Nabet, et al.
PDF
Works count: 39
Citation count: 1,758
H-index: 9
I10-index: 9
Year
Topic
Type